Abstracts from the upcoming American Society of Clinical Oncology (ASCO) annual meeting are out, published on Wednesday evening. The totality of data present in the abstracts isn’t particularly exciting, but here we’ve followed up on a few of the more volatile names that PropThink previewed last week.
Incyte’s (INCY) Jakafi in pancreatic cancer, polycythemia vera and ‘360.
INCY dropped 8% in the Thursday session following a somewhat disappointing “big reveal” related to its lead and already approved cancer drug, Jakafi (ruxolitinib). Incyte has been talking up a subset of pancreatic cancer patients in a phase 2 study who performed better taking Jakafi in combination with capecitabine than the aggregate study population taking the same combination. Analysts and investors have been eager to understand exactly what made patients more responsive to the combination in order to estimate the potential market and the drug’s feasibility.
Already a Premium user? Sign In
